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Breast cancer affects one in eight women throughout the course of their lifetimes 
creating an immediate demand for novel prevention strategies against this disease.  The 
Notch signaling pathway is often aberrantly activated in human malignancies including 
breast cancer.  Alpha secretases, including A Disintegrin and Metalloprotease (ADAM)-
10 and -17, are proteases that play a key role in the cleavage of cell surface molecules 
and subsequent ligand-mediated activation of Notch signaling pathway.  High expression 
levels of ADAM10 are clinically associated with lower disease-free survival in breast 
cancer patients.  The goal of this study was to determine the effect of diallyl trisulfide 
(DATS), a bioactive organosulfide found in garlic and other Allium vegetables, on Notch 
pathway components, specifically alpha secretases, in an in vitro model of breast cancer.  
Here we report for the first time that DATS inhibits the expression of ADAM10 and 
ADAM17 in estrogen-independent MDA-MB-231 and estrogen-dependent MCF-7 breast 
cancer cells, as well as in Harvey-ras (H-Ras) transformed MCF10A-H-Ras breast 
epithelial cells.  We also show that DATS inhibits the Notch ligands Jagged-1 and 
Jagged-2.  Furthermore, we show that DATS treatment reduces overall cell viability in 




viability of normal-like breast epithelial MCF-12A cells to a lesser extent.  DATS 
induces a dose-dependent reduction in colony formation ability of MDA-MB-231 and 
MCF-7 breast cancer cells.  Collectively, our results show that DATS modulates Notch 
pathway components deregulated in breast cancer cells and may serve as a functionally 




CHAPTER 1. INTRODUCTION 
1.1 Introduction to Breast Cancer 
Cancer remains a major public health concern in 2016.  An estimated 1.68 million 
new cases of cancer will be diagnosed in the US in 2016, with nearly a quarter of a 
million cases coming from breast cancer (1).  Breast cancer has a one-in-eight lifetime 
risk in women and is projected to result in nearly 41,000 deaths in 2016 (1).  The 
incidence of breast cancer among women has varied over the past forty years.  A sharp 
increase in diagnoses occurred throughout the 1980s and 1990s, an effect largely 
attributed to the increased prevalence of mammography at that time (2).  Conversely, 
incidence dropped considerably from 2002-2003 following publication of a report linking 
use of menopausal hormones with increased risk of breast cancer (3–5).  Since this time, 
breast cancer incidence in the US has remained relatively stable. 
Breast cancer is frequently classified based on the presence or absence of clinically 
significant molecular markers expressed in the tumor tissue, including hormone receptors 
and human epidermal growth factor receptor 2 (HER2) (6,7).  This classification system 
groups breast cancer patients into four major categories (Table 1.1).  The first category is 
Luminal A, which is positive for estrogen receptor (ER) and/or progesterone receptor (PR) 
and does not overexpress HER2.  Luminal B breast cancer is positive for ER and/or PR 




Table 1.1 Sub-classifications of breast cancer based on expression of clinically significant 
molecular markers. 
Classifications of breast cancer subtypes based on presence or absence of estrogen 
receptor, progesterone receptor, and HER2.  + symbol in table indicates positive 
expression of molecular marker, - symbol in table indicates negative expression of 






Luminal A + - 
Luminal B + + 
HER2+ - + 
Triple-Negative - - 
 
but absence of both hormone receptors.  Finally, triple negative breast cancer lacks 
expression of ER, PR, and HER2.  Luminal A breast cancer is both the most commonly 
occurring type of breast cancer and the most favorable in prognosis, as the presence of 
hormone receptors makes these cancer cells susceptible to hormone-focused treatment 
strategies (7).  HER2+ breast cancer represents 4% of all breast cancer cases and has a 
favorable prognosis due to the clinical efficacy of trastuzumab, a monoclonal antibody 
which targets HER2 (7).  Triple-negative breast cancer accounts for 12% of breast cancer 
cases and currently lacks a targeted treatment strategy (7). 
Heterogeneity in cancer dictates treatment strategies and plays a role in predicting 
survival.  Intertumor heterogeneity, the variability in the molecular signature between 
two patients, determines the appropriate drugs for treating individual patients (7).  
Intratumor heterogeneity, defined as the variability of molecular subtypes within a single 
tumor, presents a unique set of challenges (8).  First, a single biopsy of the primary tumor 
may not capture the full diversity of molecular signatures represented in the tumor, as 




biopsies can lead to improper treatment selection if not all subclones within the tumor 
were identified by biopsy.  Improper or inadequate treatment can then induce a shift in 
dominance to unaffected subclones and permit survival of the tumor (8).  Intratumor 
heterogeneity also permits intermetastatic heterogeneity, or the heterogeneity between 
different metastatic lesions within a single patient (10).  The presence of many clones 
within the primary tumor creates variation in molecular signatures at metastatic lesions, 
decreasing the probability of effectively treating the cancer at each site (10).  One 
solution to the challenges of heterogeneity in cancer is the use of multiple targeted anti-
cancer drugs in tandem to maximize cancer cell kill.  Polypharmacy, however, has its 
own set of challenges including patient burden and drug-drug interactions (11).   
Epidemiological data has long suggested a correlation between specific foods and 
food groups and risk of cancer.  Consumption of whole fruits and vegetables is associated 
with protection from several types of cancer, including breast cancer (12).  More 
specifically, epidemiological research examining consumption of cruciferous vegetables, 
soy, green tea, red wine, and Allium vegetables including garlic and onions (12–17) has 
identified inverse relationships between consumption of these specific foods and 
development of cancer.  Consumption of  Allium vegetables was inversely associated 
with breast cancer development in a case-control study completed in Lorraine, France 
(17).  Women consuming 11-12 servings of garlic and onions per week had an adjusted 
odds ratio of 0.25 (95%CI: 0.11-0.55, P-value < 10-6) for breast cancer compared to 
women consuming ≤ 6 weekly servings (17).  A case-control study conducted in Italy and 
Switzerland reported an odds ratio of 0.75 (95%CI: 0.50-1.12, P-value = 0.08) for breast 




consumers (18).  An inverse association between garlic consumption and cancer 
incidence was also found in a meta-analysis of stomach and colorectal cancers (19).  The 
results collectively suggest a protective role of Allium vegetables in development of 
multiple types of cancer, including breast cancer. 
 
1.2 Synthesis and Pharmacokinetics of Diallyl Trisulfide 
Diallyl trisulfide (DATS) has been identified as one of the most bioactive 
components of the Allium vegetable garlic (20).  Below we discuss synthesis, 
pharmacokinetics, and mechanisms of action of DATS in cancer cells. 
DATS is synthesized from its precursor, gamma-glutamyl-S-allyl-L cysteine, which 
is naturally present in the garlic clove (Figure 1.1) (21,22).  Gamma-glutamyl-S-allyl-L 
cysteine can convert to S-allyl cysteine, a water-soluble and non-volatile compound with 
antioxidant properties (21–23).  It can also convert to alliin, with gradual accumulation of 
alliin occurring throughout storage of intact cloves (21).  Crushing or chewing liberates 
alliinase from the bundle sheath cells of the clove, allowing it to convert alliin to allicin 
(21,23,24).  Allicin is unstable and spontaneously decomposes to lipid-soluble 
organosulfides including DATS, among others (21,24).  Alliin accounts for 
approximately 1% of whole garlic and is odorless; its enzymatic product allicin, however, 
has the pungent aroma characteristic of fresh garlic (21,24).  DATS, too, is a volatile 
compound (24).  DATS is more abundant than its related compounds, diallyl disulfide 
and diallyl sulfide, with an estimated 900-1100 μg of DATS per g of garlic (25,26).  A 





Figure 1.1 Synthesis of diallyl trisulfide and related organosulfides.   
Adapted from reference (22). 
 
Pharmacokinetic data on DATS in humans is sparse and critically needed.  Animal 
models, however, provide some insight on DATS pharmacokinetics.  For example, a 10 
mg injection of DATS administered to the jugular vein in rats resulted in 30 μmol/L 
maximum DATS concentration in the blood (27).  Concentrations of DATS rapidly 




Methods of extending the half-life of DATS in the blood have been attempted.  
Incorporation of DATS into a microemulsion prior to a 30 mg/kg intravenous injection in 
Sprague Dawley rats increased the maximum concentration of DATS in blood to 
approximately 40 μmol/L, compared to 30 μmol/L achieved without the microemulsion 
(27,28).  The Tmax of DATS following the microemulsion injection was 3 h (28).  In 
humans, oral consumption of up to 25 g of raw, chopped garlic did not result in 
detectable levels of allicin, DATS, or other organosulfides in the blood or urine 1, 2, 4, or 
24 h after consumption (29).  Given that the Tmax of DATS administered directly to the 
blood of rats was one minute (27), testing human blood one hour after garlic ingestion 
may not have captured peak concentrations of DATS.  Ingestion of DATS may result in 
storage of DATS in the liver or other organs.  The possibility of DATS storage in organ 
tissue is supported by the observation that vinyl dithiins, a product of allicin degradation, 
is stored in the livers of rats (30).  Further pharmacokinetic data are critically needed. 
 
1.3 Clinical Trial of Diallyl Trisulfide 
In a clinical trial completed in China, approximately 5000 men and women were 
randomized to orally consume 200 mg of DATS every day and 100 μg of selenium every 
other day for the month of November in 1989, -90, and -91 (31).  Subjects were age 35-
74 y and had a medical history of stomach disorders, family history of cancer, smoked or 
consumed alcohol, or had some combination of these four inclusion criteria.  Five years 
after completion of the intervention, there was a 22% decrease in morbidity rate of all 
cancers and a 47% decrease in the rate of gastric cancer in those receiving DATS and 




following intervention were 0.67 for all cancers (95%CI: 0.43-1.03) and 0.48 for stomach 
cancer (95%CI: 0.21-1.06).  Among men, the relative risks were 0.51 (95%CI: 0.30-0.85) 
for all cancers and 0.36 (95%CI: 0.14-0.92) for stomach cancer.  Among women, the 
intervention did not significantly modulate cancer risk.  The researchers noted that this 
may be a result of a smaller sample size for women compared to men (n=3250 for men, 
n=1783 for women) or the lower incidence of gastric cancer among women (31).  The 
results of this clinical trial highlight the safety of oral DATS administration for a 
prolonged period of time and may suggest a role for DATS in cancer chemoprevention.  
The safety and anticancer effect of DATS have also been identified in animal models of 
cancer. 
 
1.4 Mechanisms of Action of Diallyl Trisulfide in vivo and in vitro 
Animal models of cancer exemplify the safety and efficacy of DATS against cancer 
cell growth.  MCF-7 breast cancer xenograft nude mice, for example, upon receiving 5 
μmol/kg body weight DATS by oral gavage twice weekly for one month, displayed 
reduced tumor volume 3 months following inoculation compared to control-treated mice 
(32).  DATS treatment also reduced tumor size in PC-3 prostate cancer xenograft animals 
(33).  Importantly, treating SUM159 breast cancer xenograft mice with 2 mg DATS three 
times weekly did not decrease body weight (34), suggesting DATS is non-toxic to major 
organs. 
The anticancer effect of DATS has been researched in cell culture models of 
pancreatic, stomach, colon, prostate, and breast cancer, among others (35–39).  DATS 




reactive oxygen species generation was inhibited by overexpression of the c-Jun N-
terminal Kinase (JNK) inhibitor JNKK2 in DU145 prostate cancer cells, suggesting that 
DATS induces activation of JNK and subsequent generation of reactive oxygen species 
(40).  JNK activation, however, was inhibited by the antioxidant N-acetylcysteine in 
MCF-7 breast cancer cells, indicating that reactive oxygen species may play a role in 
JNK activation (32).  Generation of reactive oxygen species following DATS treatment is 
associated with induction of apoptosis and cell cycle arrest in cancer cells. 
DATS is a known inducer of apoptosis in cultured cancer cells.  DATS treatment 
induced de-activating phosphorylation of the anti-apoptotic protein Bcl-2 in cultured 
prostate cancer cells (42).  Increased Bcl-2 phosphorylation was also observed in tumors 
from PC-3 prostate cancer xenograft mice treated with 6 μmol DATS, delivered three 
times a week by oral gavage (33).  Phosphorylation of Bcl-2 by DATS was suppressed by 
the JNK inhibitor SP600125 in prostate cancer and breast cancer cells (32,42).  The effect 
of DATS on apoptosis was blunted following addition of N-acetylcysteine or 
overexpression of catalase (41,42).  In cell models of breast cancer, DNA fragmentation 
was observed in estrogen-independent MDA-MB-231 and estrogen-dependent MCF-7 
breast cancer cells following DATS treatment (39), suggesting that DATS induces 
apoptosis independent of ER status.  The data collectively suggest that DATS treatment 
induces apoptosis in multiple types of cancer, is associated with JNK activation and 
reactive oxygen species generation, and is independent of hormone receptor status in 
breast cancer cells. 
DATS treatment induces cell cycle arrest in cancer cells.  Specifically, cell models 




cell cycle arrest was not observed in normal prostate epithelial cells cultured with DATS 
at a similar concentration (43).  DATS decreased expression of Cdc25C and induced 
expression of cyclin B1, both of which play a role in entry to mitosis (43,44).  DATS-
mediated cell cycle arrest was attenuated by co-treatment with N-acetylcysteine as well 
as knock-down of checkpoint kinase-1 in prostate cancer cells (43,45).  The results 
indicate that DATS induces G2/M cell cycle arrest in cancer cells, and is associated with 
reactive oxygen species generation. 
DATS also plays a role in reducing cell migration and invasion, and the cancer stem 
cell (CSC) population.  DATS treatment reduced passage of MDA-MB-231 cells through 
Transwell chambers and delayed wound healing in an in vitro scratch assay (46,39).  
DATS treatment induced expression of the cell-cell adhesion protein E-cadherin and 
suppressed vimentin and matrix metalloproteases-2 and -9, collectively suggesting a role 
for DATS in suppression of cancer cell migration and invasion (46,39).  Most recently, 
DATS treatment was shown to inhibit the CD44high/CD24low/ESA+ sub-population of 
estrogen-dependent MCF-7 and triple-negative SUM159 breast cancer cells, as well as 
sphere formation in both cell lines (34).  Aldehyde dehydrogenase-1 (ALDH1) activity 
was inhibited by DATS treatment in vitro and in vivo (34).  The combined results suggest 
that DATS can target the breast CSC population (34).  Inhibition of breast CSCs by 
DATS was mediated by inhibition of FoxQ1 in SUM159 cells, although the near absence 
of FoxQ1 protein in MCF-7 cells suggests other mechanisms may contribute to CSC 
inhibition by DATS (34).   
Several other pathways may contribute to CSC inhibition by DATS.  Embryonic 




activated in cancer cells and can contribute to CSC self-renewal.  In cultured U2OS, 
SaOS-2, and MG-63 osteosarcoma cells, DATS down-regulated expression of the 
cleaved Notch-1 receptor and the downstream Notch targets Hes-1, Hey-1, and cyclin D1 
(47).   
 
1.5 Notch Signaling Pathway and Clinical Significance 
The Notch signaling pathway, while indispensable in embryonic development, 
plays a key role in tumor growth in several types of cancer, including breast cancer (48–
50).  In addition to its role in cell proliferation, Notch regulates angiogenesis, the 
epithelial to mesenchymal transition (EMT), and the CSC population in tumor cells (51–
53).  The many diverse downstream processes regulated by Notch highlight this pathway 
as a potential therapeutic target in cancer.  
Notch is a type of juxtacrine signaling pathway which requires direct contact 
between neighboring cells for pathway activation (Figure 1.2) (54).  Notch ligands, 
including Jagged-1, Jagged-2, and Delta-like (DLL)-1, -3, and -4, are expressed on the 
signal-sending cell, and physically interact with Notch receptors (Notch-1, -2, -3, -4) on 
neighboring signal-receiving cells.  Binding of a Notch ligand to a Notch receptor 
induces a conformational change in the receptor which permits A Disintegrin and 





Figure 1.2 Notch signaling pathway. 
Binding of Notch ligands, including Jagged-1, permits cleavage of Notch receptor first by 
ADAM10, and then by the gamma secretase complex.  The liberated Notch intracellular 
domain (NICD) then translocates to the nucleus and activates transcription. 
 
Cleavage of Notch extracellular domain is followed by cleavage of the Notch 
intracellular domain (NICD) by the gamma secretase complex.  The liberated NICD then 
translocates to the nucleus where it binds and activates the transcription factor 
recombinant signal binding protein for immunoglobulin kappa J region (RBP-Jκ).  
Targets of the Notch signaling pathway include Hes and Hey family members, as well as 
proteins involved in cell growth including cyclin D1 and c-myc (56,57).  Inhibition of 




ADAM10 and ADAM17, is a potential method of suppressing Notch pathway activity in 
cancer.  The Notch ligands Jagged-1 and Jagged-2 are overexpressed in breast cancer 
tissue compared to surrounding normal breast tissue, and high tumor expression of either 
ligand is associated with reduced survival in breast cancer patients (58–62).  ADAM10 
and ADAM17 are also critically involved in Notch pathway activation.  ADAM10 
mRNA is overexpressed in breast cancer tissue compared to normal breast tissue, and 
high expression of ADAM10 inversely correlates with survival in breast cancer patients 
(63–65).  ADAM17 expression is directly correlated with tumor grade and inversely 
associated with survival in breast cancer patients (66).  Collectively, the results indicate 
that targeting Notch ligands and alpha secretases is clinically relevant in breast cancer 
patients. 
Efforts to inhibit Notch signaling in cancer patients have focused primarily on 
development of gamma secretase inhibitors (GSIs).  GSIs have effectively reduced tumor 
size in animal models, however, use of GSIs in humans is associated with unacceptable 
gastrointestinal side effects including diarrhea (49,67).  Inhibition of ADAM and related 
matrix metalloprotease protein families has been attempted in the past for treatment of 
rheumatoid arthritis (68).  These attempts, however, were accompanied by 
musculoskeletal side effects which limited efficacy of clinical testing (68).  Recent 
approaches to inhibiting ADAM10 and ADAM17 in cancer include development of a 
monoclonal antibody (69), as well as specific low-molecular weight inhibitors including 
INCB3619 and INCB7839 (70–73).  Interestingly, a clinical trial of INCB7839 combined 
with trastuzumab in HER2+ breast cancer patients seemed to yield positive results 




establish the safety and efficacy of this drug.  While use of dietary agents to modulate 
ADAM family members has been reported in models of Alzheimer’s disease (74), 
inhibition of ADAMs with dietary agents in cancer has not been explored. 
In the current study, we hypothesized that DATS inhibits Notch signaling pathway 
in breast cancer cells.  We first utilize a trypan blue assay to show that DATS inhibits 
viability of MDA-MB-231 and MCF-7 breast cancer cells, and the Harvey-ras (H-Ras) 
transformed MCF10A-H-Ras breast epithelial cell line.  Viability of MCF-12A cells, a 
model of normal breast epithelial tissue, following DATS treatment was affected to a 
lesser extent compared to breast cancer cells.  In addition, DATS blocks colony 
formation in MDA-MB-231 and MCF-7 breast cancer cells in an in vitro clonogenic 
assay.  We also report a novel mechanism of action of DATS by inhibiting protein 
expression of ADAM10 and ADAM17 in cultured breast cancer cells.  The Notch ligands 
Jagged-1 and Jagged-2 are inhibited by DATS treatment, suggesting that DATS may play 




CHAPTER 2.  MODULATION OF NOTCH SIGNALING PATHWAY BY DIETARY 
AGENTS 
2.1 Introduction 
Notch was first identified in Drosophila by observation of a notched wing 
phenotype in mutation-bearing flies (75).  Years later, an activating mutation in the Notch 
receptor was discovered in T-cell acute lymphoblastic leukemia, implicating the pathway 
in cancer initiation (76–78).  Since then, dysfunctional Notch signaling has been 
identified in a number of other cancer types including breast, lung, and glioma, among 
others (49,50). 
Downstream targets of Notch signaling, while context-dependent, include proteins 
related to cell cycle progression, cell survival, and cell fate decisions.  These proteins are 
particularly crucial for proper embryonic development in mammals, although the 
pathway maintains relevance in adults as well.  In adults, Notch maintains tissue-specific 
stem cell populations, such as those found in the intestinal crypts, through the process of 
self-renewal (54,79).  By extension, aberrantly activated Notch maintains the CSC 
population in transformed cells (80).  Notch-mediated CSC maintenance, combined with 
the pathway’s role in promoting cell survival and proliferation, helps establish a rationale 
for targeting Notch in cancer treatment.  Further strengthening the argument for targeting 
Notch in cancer is an array of clinical data in which expression of Notch pathway 




(50,60).  In accordance with this observation, several therapeutic agents have been 
designed to specifically target and inhibit Notch, although the safety and efficacy of these 
agents are still being tested (49,81,82).  As an alternative to small molecules or biologics, 
several researchers have focused their attention on the identification of novel dietary or 
natural agents which modulate Notch.  This review will critically examine the efficacy of 
several dietary and natural agents in modulation of the Notch signaling pathway in the 
context of cancer. 
 
2.2 Notch Signaling 
The Notch signaling pathway plays a role in development of cancer and in 
regulation of CSCs.  Below we describe the Notch signaling pathway, and discuss its 
relevance to cancer. 
 
2.2.1 Notch Signaling Pathway 
The Notch signaling pathway has several levels of regulation to fine-tune pathway 
activation (Figure 2.1).  In the canonical pathway, a membrane-bound Notch ligand binds 
and activates the Notch receptor on a neighboring cell.  This ligand binding event leads to 
subsequent cleavage of the Notch receptor and liberation of the NICD.  NICD, the 
pathway effector, translocates to the nucleus following cleavage, where it binds RBP-Jκ 
to activate transcription.  Within each step of this process, layers of regulation take place 
to ensure the correct level of signaling is achieved, as discussed below. 
Five single-pass transmembrane Notch ligands (DLL-1, -3, and -4, Jagged-1, and -2) 





Figure 2.1 Effect of dietary agents on Notch pathway in cancer cells in vitro. 
Notch ligands, including Jagged-1, bind to and permit cleavage of the Notch receptor.  
Notch extracellular domain is cleaved first by ADAM10; Notch intracellular domain 
(NICD) is then cleaved by gamma secretase.  NICD activates transcription in the nucleus.  
Dietary agents that modulate Notch in cancer cells in vitro are listed. 
 
receptors is referred to as trans activation, that is, the ligand present on one cell activates 
a receptor on a neighboring cell (83).  Notch ligands that are co-expressed in the same 
cell as the Notch receptor display cis-inhibition, and block Notch pathway activation (84).  
The mechanism by which this occurs may involve spatial and temporal restrictions in 
ligand or receptor expression, as well as ligand-to-receptor ratios (83,84).  Recent work 




expression of specific Notch ligands (Delta versus Jagged) and driven in part by the 
activity of Fringe (85). 
Notch ligands activate one of four membrane-bound Notch receptors (Notch-1, -2,  
-3, -4).  Following transcription and translation of the full-length Notch receptor, the 
polypeptide is cleaved (S1 cleavage) by furin-like proteases to yield the mature form of 
the receptor which embeds in the plasma membrane.  The receptor itself is categorized 
into discrete domains.  The extracellular domain is comprised of 29-36 tandem epidermal 
growth factor (EGF)-like repeats, of which 11-12 are required for signal activation and 
24-29 are associated with cis-inhibition (54).  The extracellular domain also homes a 
negative regulatory region which blocks pathway activation in the absence of Notch 
ligands.  The EGF repeats are frequently modified with sugar groups, which may play a 
role in specific ligand binding and overall pathway activity (83,85).  The intracellular 
Notch domain is comprised of an RBP-Jκ association molecule domain, 7 ankyrin repeats, 
and a C-terminal PEST domain (rich in amino acids proline, glutamic acid, serine, and 
threonine).  The PEST domain is subject to phosphorylation and ubiquitination events 
which determine the rate at which the Notch intracellular domain is degraded (83). 
Contact between a ligand and receptor induces S2 cleavage of Notch, liberating the 
Notch extracellular domain which is endocytosed into the ligand-expressing cell (54).  S2 
cleavage is performed by the alpha secretase ADAM10.  The S2 cleavage site is 
embedded in Notch’s negative regulatory region, suggesting that binding of a Notch 
ligand must induce a conformational change in Notch that permits access of the S2 site to 
ADAM10 (54).  Notch can also be activated by ligand-independent mechanisms (86).  




transport to the lysosome for degradation.  The Notch receptor may be “accidentally” 
cleaved from endocytic vesicles prior to arrival at the lysosome and degradation, thereby 
activating Notch signaling in the absence of a Notch ligand (86).  Additionally, Notch 
receptors can be cell-autonomously activated in the absence of inhibitory cis ligands (86).  
Finally, deletions in the negative regulatory region of the Notch receptor, such as those 
found in T-cell acute lymphoblastic leukemia (T-ALL), permit ligand-independent 
pathway activation (78).  ADAM17 preferentially performs S2 cleavage under such 
ligand-independent circumstances (87). 
Shedding of the Notch extracellular domain by ADAM10 or ADAM17 yields a 
membrane-tethered Notch intracellular fragment called Notch extracellular truncation.  
This shedding event permits S3/S4 cleavage of Notch extracellular truncation, which is 
performed by the gamma secretase complex.  Presenilin  is the active component of the 
gamma secretase complex, and is associated with other core proteins including nicastrin, 
anterior pharynx defective-1, and presenilin enhancer-2 (88).  Gamma secretase cleavage 
liberates the intracellular fragment NICD. 
NICD translocates to the nucleus where it binds RBP-Jκ, a DNA-binding protein.  
Binding of NICD to RBP-Jκ induces recruitment of mastermind-like and the 
transcriptional activation complex while simultaneously displacing transcriptional 
repressors.  The result is conversion of RBP-Jκ from a transcriptional repressor to a 
transcriptional activator.  Expression of Notch target genes is highly context-dependent 
and varies considerably between different cell types.  Classic Notch downstream targets 
include the basic helix-loop-helix transcriptional repressors Hes and Hey family members.  




such as cyclin D1, those involved in cell survival such as c-myc, and several others 
(50,89).   
Members of the Hes and Hey family of proteins are frequently used as a measure of 
pathway activation given their ubiquitous activation following Notch stimulation.  Hes 
proteins may, however, play a role in Notch pathway inhibition, creating a negative 
feedback loop.  Evidence of this feedback has been noted in neural development, 
embryonic stem cells, and recently in breast cancer (90–92).  Alternatively, RBP-Jκ 
reporter activity and NICD levels have also been used as indicators of pathway activation, 
although this latter method depends on detection of what is, in some contexts, a short-
lived protein (80). 
 
2.2.2 Cross Talk 
Notch signaling cross talks with several pathways including Ras, Wnt, nuclear 
factor kappa B (NF-κB), Janus Kinase/Signal Transducer and Activator of Transcription 
(JAK/STAT) signaling and others (80).  Simultaneous overexpression of Ras and Notch-
1 induced malignant transformation of HMLE breast epithelial cells, while 
overexpression of either of these two genes alone did not result in transformation, 
suggesting a cooperative relationship between the pathways (58).  The Notch ligand 
Jagged-1 is a transcriptional target of Wnt signaling pathway (93).  In addition, β-catenin, 
a component of Wnt signaling pathway, can directly bind NICD in HEK293 cells; and 
overexpression of β-catenin increases Hes-1 reporter activity in mouse embryonic 
fibroblasts (94).  These data suggest that Wnt activation can augment Notch pathway 




JAK/STAT, as these are immediately relevant to our discussion of modulation of Notch 
with dietary agents in cancer cells. 
An elaborate review of cross talk between Notch and NF-κB in the context of 
cancer is available (95), and we will address recent discoveries in the field.  Prior to 
pathway stimulation, NF-κB is sequestered in the cytosol by inhibitor of κB (IκB).  
Pathway stimulation activates IκB kinase (IKK), composed of IKKα, IKKβ, and IKKγ.  
Activated IKK phosphorylates IκB, leading to its ubiquitination and subsequent 
degradation.  Degradation of IκB liberates NF-κB such that it may translocate to the 
nucleus where it acts as a transcription factor for downstream targets which promote cell 
proliferation, evasion of apoptosis, and an inflammatory response (96,97).   
Cross talk between NF-κB and Notch is bidirectional.  Inhibition of Notch activates 
the IKK complex, thereby deactivating NF-κB (98,99).  This relationship may be 
explained by an inhibitory effect of Hes-1 on IKK (100).  Furthermore, DLL-4 and 
mastermind-like-1 enhance NF-κB activation, while Numb-like, a Notch pathway 
inhibitor, suppresses the pathway (101–104).  Conversely, NF-κB also potently regulates 
Notch signaling.  Deletion of IKKβ suppresses Hes-1 and Hey-1 expression (105).  
Similarly, binding of p65, a protein component of NF-κB, near the Notch-1 promoter 
enhances Notch-1 gene expression (106).  In basal breast cancer, NF-κB signaling 
induced expression of the Notch ligand Jagged-1 (107).  NF-κB-mediated induction of 
Jagged-1 led to CSC growth (107), indicating a critical role for NF-κB activation in CSC 
maintenance.  The bi-directional nature of Notch and NF-κB crosstalk suggests that 




JAK/STAT activation is achieved upon ligand binding to membrane-bound JAK 
proteins.  JAKs then phosphorylate and activate STAT proteins, leading to their nuclear 
localization and transcriptional activation of target genes including Bcl-xL and p21 (108).  
Similar to NF-κB, Notch signaling overlaps with JAK/STAT signaling in a bidirectional 
manner.  Hes-1 and Hes-5 both induce activating phosphorylation of STAT3, promoting 
pathway activation  (109,110).  Inhibition of STAT3 reduced gene expression of Notch 
pathway components, including Notch-1 and Jagged-1 (106).  Similar to NF-κB, dietary 
agents may play a direct role in regulation of Notch, or an indirect role through 
modulation of JAK/STAT activity. 
 
2.2.3 Notch and Cancer Stem Cells 
Of particular interest in cancer biology is the role of Notch in regulation of the CSC 
population.  CSCs are described as a tumorigenic sub-population of cancer cells 
responsible for driving continuous growth of the tumor.  Grafting as few as 100 sorted 
CSCs into mice leads to robust tumor formation in models of several types of cancer 
(111–115).  The ability of CSCs to generate tumors in vivo is attributed to their unique 
pattern of cell division.  Similar to their normal tissue counterparts, CSCs divide 
asymmetrically such that one daughter cell self-renews to maintain the CSC population, 
while the second daughter cell differentiates into a proliferative, committed progenitor 
cell (116).  Continued proliferation of progenitor cells permits expansion of a 
heterogeneous bulk tumor cell population. 
While differentiated bulk tumor cells are often susceptible to treatment, CSCs are 




ALDH in CSCs contributes to drug efflux and aldehyde detoxification, respectively, in 
cell models of breast cancer (117–121).  Collective expression of these proteins 
contributes to the treatment resistance and longevity of not only CSCs but also normal 
tissue stem cells (121,122).  The ability of CSCs to resist conventional treatment, 
combined with their tumorigenic capacity, permits the regrowth of tumors following 
treatment and subsequent patient relapse.  Treatment resistance and self-renewal capacity 
of these cells also increase their appeal as therapeutic targets, especially for prevention of 
cancer metastasis. 
There is much debate over the exact origin of CSCs, and two hypotheses currently 
rule our understanding (123).  The first is that CSCs are genetically mutated versions of 
their normal tissue stem cell counterparts.  The second view is that CSCs arise from de-
differentiation of cancer cells.  There is evidence for both models, suggesting that the two 
models are not mutually exclusive.  Below we discuss both theories as they relate to 
Notch signaling. 
The strength of evidence supporting that Notch contributes to normal stem cell and 
CSC maintenance is strong, although the precise understanding of how Notch promotes 
self-renewal is somewhat incomplete.  Recent work demonstrates a critical role of Notch 
for CSCs in vitro and in vivo (124).  MCF-7 and SUM159 human breast cancer cell lines 
were transfected with an RBP-Jκ/Notch reporter construct and Notch activity was 
identified by level of green fluorescent protein (GFP) expression (124).  Cells with high 
GFP expression were identified as Notch+ cells (124).  Notch+ cells demonstrated 
enhanced sphere forming ability and Notch-4 message expression compared to Notch- 




in non-obese diabetic/severe compromised immunodeficient (NOD/SCID) mice 
compared to Notch- counterparts (124).  Most interestingly, sorted Notch+ cells were 
able to generate Notch+ and Notch- cells in vitro and in vivo, suggesting that Notch+ 
cells possess stem-cell characteristics (124).  Cultured Notch- cells, in comparison, 
remained Notch- throughout a 12-week incubation period (124).  This study provides 
evidence for an overlap between cells which express Notch and the CSC population.  In 
agreement with this, siRNA against Notch-1 significantly reduced viability of ALDH+ 
MDA-MB-231 breast cancer cells (125).  Notch-1 siRNA also inhibited sphere formation 
in breast cancer cells (126).  Overexpression of Notch-1 or Notch-2 by plasmid 
transfection, conversely, enhanced sphere formation in B16 melanoma cells (127).  
Collectively, the evidence suggests a role for Notch in CSC maintenance and self-
renewal and highlights this pathway as a potential therapeutic target in cancer treatment. 
The precise mechanism by which Notch signaling maintains CSCs in a state of 
pluripotency is incompletely understood.  Several genes downstream of Notch have been 
implicated for a role in CSC maintenance including Sox9, c-Myc, and Nanog 
(57,128,129).  Sox9 plays a role in the maintenance of neural stem cells, and combined 
with the transcription factor Slug, plays a role in mammary stem cell maintenance 
(130,131).  Sox9 was identified as a direct Notch target gene, with ten RBP-Jκ binding 
sites in its regulatory region (128).  c-Myc has also been identified as a key regulator of 
stem cell self-renewal and is directly modulated by Notch signaling (57,132).  Nanog is 
critical for self-renewal of embryonic stem cells (133,134).  While an RBP-Jκ binding 
site was not identified in Nanog regulatory regions, treatment of MDA-MB-231 breast 




expression of NICD-1 (135),  resulted in a 10-fold decrease in Nanog protein (129).  
Interestingly, doxycycline-induced overexpression of Nanog in xenografted MCF-7 
breast cancer cells resulted in enhanced drug resistance concurrently with increases in 
ALDH1 and ATP-Binding Cassette subfamily G-2 gene expression, highlighting the 
significance of Nanog expression in breast CSC maintenance (136).  Induction of self-
renewal genes by Notch pathway activation is a likely mechanism by which Notch 
maintains CSCs. 
In accordance with the theory of de-differentiation, there is much support for a 
transition from an epithelial to a mesenchymal phenotype in the acquisition of stemness.  
Notch induces expression of EMT-activating transcription factors, including Snail, Slug, 
Twist, and ZEB (53).  Slug suppresses the expression of epithelial markers such as 
claudins and occludins, as well as the adhesion protein E-cadherin (137), contributing to 
a migratory phenotype.  Importantly, normal mammary epithelial cells which are forced 
to undergo EMT by ectopic expression of Twist or Snail underwent an expected shift 
toward a mesenchymal phenotype as well as enrichment of the CD44high/CD24low cell 
population and a significant increase in sphere-forming ability (138).  The overlapping 
expression of signature EMT transcription factors with characteristics of CSCs suggests a 
relationship or overlap between the two cell populations which is modifiable by Notch.  
To conclude, Notch signaling plays a key role in maintaining the highly tumorigenic CSC 
population.  Current evidence suggests that Notch-mediated CSC maintenance occurs 






2.2.4 Clinical Relevance of Notch in Cancer Development 
Clinical data indicate that components of the Notch signaling pathway are 
associated with reduced survival in several types of cancer.  Expression of the Notch 
ligand DLL-4 is inversely associated with overall survival in a meta-analysis of non-
small cell lung cancer, and high DLL-1 expression is associated with shorter survival in 
acute myeloid leukemia (139,140).  High levels of DLL-4 in acute myeloid leukemia 
served as an independent predictor for relapse-free and overall survival (140).  The Notch 
ligands Jagged-1 and Jagged-2 were found to be more highly expressed in invasive ductal 
carcinoma compared to normal breast tissue (58).  Importantly, the Notch ligand Jagged-
1 was highly expressed in 78% of invasive ductal carcinoma patients, as determined by 
immunohistochemistry, highlighting the ubiquitous nature of this target among invasive 
breast cancer patients (59).  Breast cancer patients with high tumor Jagged-1 expression 
had a 42% 5-year survival rate compared to 65% 5-year survival among women with low 
tumor Jagged-1 expression (60).  The 5-year survival rate further dropped to 32% in 
breast cancer patients with tumors which highly expressed both Jagged-1 and  Notch-1 
(60).  In addition, breast cancer patients with high tumor Jagged-1 expression had an 
increased likelihood of relapse compared to those with low expression (61).  High levels 
of Jagged-1 may also correspond with poor prognosis in gastric cancer and possibly in 
acute myeloid leukemia, although this observation in acute myeloid leukemia is 
controversial (140–142).  High expression of Jagged-2, as well, in breast tumors 
correlates with poorer overall survival and metastasis-free survival (62).  The results 
collectively demonstrate induction of Notch ligand expression in several human 




Overexpression of Notch receptors is also associated with poor prognosis in cancer 
patients.  High Notch-1 expression levels serve as independent prognostic predictors in 
both gastric cancer and acute myeloid leukemia (140,141).  In non-small cell lung cancer, 
high tumor Notch-1 and Notch-3 expression was associated with higher levels of lymph 
node metastasis, but only Notch-3 expression was inversely correlated with overall 
survival (139).  Similar to Jagged-1, high expression of Notch-1 and Notch-3 was 
associated with reduced probability of survival among breast cancer patients (60).  In 
non-small cell lung cancer, low levels of Hes-1 were linked with improved survival, 
suggesting a protective role of pathway suppression (139).  Collectively, these 
associations continue to support a rationale for targeting the Notch signaling pathway in 
cancer treatment. 
Expression of gamma secretase components as well as alpha secretases ADAM10 
and ADAM17 is also inversely associated with survival in cancer patients.  Expression of 
Presenilin-1, the active component of the gamma secretase complex, is inversely 
associated with overall survival in gastric cancer (143).  High levels of ADAM10 are 
associated with reduced overall survival and high aggressiveness in nasopharyngeal 
carcinoma (144).  In triple-negative and HER2+ breast cancer patients, high expression of 
ADAM10 is associated with poor survival (64,65).  Expression of ADAM17 is also 
inversely associated with patient survival in breast cancer and clear cell renal cell 
carcinoma (66,145,146). 
Several approaches to inhibiting Notch signaling in cancer are undergoing active 
research.  Use of GSIs to limit Notch pathway activation has gained a great deal of 




also under investigation.  These strategies have been reviewed (49,81,82).  GSI use in 
cancer is associated with undesirable side effects, including diarrhea, nausea, and 
vomiting (147).  A recent clinical trial shows that administration of the GSI MK0752 and 
docetaxel to patients with metastatic or locally advanced breast cancer may reduce the 
breast CSC population, however, the drug combination resulted in diarrhea, pneumonitis, 
and altered liver function tests (148).  More recently, inhibition of alpha secretases 
including ADAM10 and ADAM17 has gained attention for Notch inhibition in cancer. 
ADAM and matrix metalloprotease inhibitors have been used for treatment of 
rheumatoid arthritis, although the occurrence of musculoskeletal side effects from this 
treatment limited drug efficacy (68).  Specific low-molecular weight ADAM inhibitors, 
as well as an anti-ADAM10 antibody, are undergoing pre-clinical and clinical testing for 
efficacy in cancer treatment (69–73).  Combination of trastuzumab and the ADAM 
inhibitor INCB7839 in HER2+ breast cancer patients reduces shedding of the HER2 
extracellular domain, although a prolonged trial is needed to determine the safety and 
efficacy of INCB7839 (73).  Modulation of ADAM10 has also been achieved with 
dietary agents including curcumin analogs in HEK293 cells (149). 
Given the crucial role of Notch signaling in normal tissue, an ideal therapeutic 
agent would specifically target Notch signaling in cancer cells while leaving Notch in 
normal tissue unaffected.  Use of diet-derived agents either alone or in combination with 
current chemotherapeutics may be a possible route for targeting Notch in cancer cells 





2.3 Modulation of Notch Pathway by Dietary Agents 
The appeal of diet-derived solutions for treatment or prevention of cancer 
originated from epidemiological data suggesting that select populations may have a lower 
cancer risk based on their dietary patterns.  Correlations have been identified between the 
Mediterranean diet, for example, and reduced cancer risk (151).  Reductionist 
examinations of diet patterns indicate that specific foods and molecules underlie the 
reduced risk of disease development, suggesting that these molecules could be used in 
chemopreventive or treatment-focused models.   
 
2.3.1 Curcumin 
Curcumin and its analogs reduced expression of Notch pathway components 
including Notch-1, Jagged-1, components of the gamma secretase complex, and Notch 
downstream targets in several cancer cell models including colon and pancreatic cancer, 
among others (Figure 2.1, Table 2.1) (152–161).  Of important note, curcumin analogs or 
alternate methods of curcumin delivery are desirable given the low bioavailability of 
curcumin from its dietary source, turmeric (161,162).  In a xenograft model of colon 
cancer, oral administration of the turmeric/phospholipid drug Meriva inhibited expression 
of NICD-1 in the tumor tissue (159) (Table 2.2).  Combining Meriva and oxaliplatin had 
a stronger inhibitory effect on tumor volume, expression of Ki-67, NICD-1, and cleaved 
caspase 3 compared to Meriva or oxaliplatin alone (159).  The inhibitory effect of 
curcumin on Notch signaling components was further underscored in an in vitro model of 
colorectal cancer in which curcumin attenuated an oxaliplatin-induced increase in NICD-




Table 2.1 Effect of dietary agents on Notch pathway components in vitro by cancer type. 
*indicates use of dietary analog, #indicates alternate delivery method e.g. nanoparticle. 
 ↑ Induced ↓ Suppressed 





























Curcumin Cholangiocarcinoma ↓    ↓  (157) 
 Colorectal*, # ↓  ↓    (159–161) 
 Esophageal ↓   ↓ ↓  (155) 
 Lymphoma ↓      (153) 
 Oral ↓    ↓ ↓ (162) 
 Osteosarcoma ↓    ↓ ↓ (156) 
 Pancreatic ↓    ↓  (152,158) 
DATS Osteosarcoma ↓    ↓  (156) 
EGCG Colorectal ↑    ↓  (163) 
 Head and Neck ↓      (164) 
 Neuroblastoma ↓      (165) 
Genistein Breast ↓      (166) 
 Neuroblastoma ↓    ↓  (167) 
 Pancreatic ↓    ↓  (168–172) 
 Prostate ↓      (173) 
PEITC Pancreatic ↓ ↓     (174) 
 Prostate    ↓   (175) 
Resveratrol Breast ↓    ↓ ↓ (176) 
 Cervical ↓ ↓   ↓  (177) 
 Carcinoids ↑      (178) 
 Glioblastoma ↑      (179) 
 Medulloblastoma ↑ ↑     (180) 
 Ovarian  ↓   ↓  (181) 
 T-ALL ↓    ↓  (182) 
 Thyroid ↑ ↑     (183) 
Retinoic Acid Breast ↓  ↓  ↓  (184) 
 Glioblastoma ↓     ↓ (185) 
 Neuroblastoma* ↓      (186) 
 Ovarian ↓      (187) 
 Pancreatic* ↓      (188) 
Sulforaphane Pancreatic ↓      (189) 
 Prostate ↑ ↑   ↑ ↑ (190) 
 Prostate ↓   ↓   (191) 





curcumin analog, effectively reduced Notch-1 protein and Notch-1 mRNA expression in 
a model of MiaPaCa2-xenograft SCID mice (Table 2.2) (158).  CDF decreased 
expression of Notch-1 protein in colon cancer cells and increased expression of the Notch 
inhibitor miR-34a (161,192).  The effect of curcumin on miR-34a is controversial, 
however, as miR-34a was inhibited by the natural form of curcumin in esophageal cancer 
cells (155).  Notch-1 was suppressed by curcumin in esophageal cancer cells (155), 
suggesting additional mechanisms by which curcumin targets Notch signaling.  
Collectively, the results support use of curcumin as a Notch inhibitor across several 
cancer types, either alone or in combination with anticancer drugs. 
Recent research indicates that increased expression or activity of ADAM10 is 
desirable for blocking development or progression of Alzheimer’s disease (74).  
Increased ADAM10 activity in models of cancer, however, may enhance cleavage and 
activation of Notch (193).  In HEK293 cells, curcumin did not affect ADAM10 
expression, however, isoleucine-, phenylalanine-, and valine-curcumin conjugates 
increased ADAM10 expression (149).  The role of curcumin in modulation of ADAM10 
specifically in cancer cells has not been researched. 
Curcumin-induced alterations in Notch signaling mediate changes in downstream 
signaling pathways including NF-κB and JAK/STAT.  Treatment of pancreatic and oral 
cancer cells with curcumin reduced NF-κB DNA-binding (152,154).  NF-κB DNA-
binding activity was reduced by curcumin treatment in pancreatic cancer cells in a Notch-
dependent manner (152).  NF-κB DNA-binding was also impaired by curcumin treatment 
in a model of oral carcinoma, however, this model did not establish whether NF-κB 





Table 2.2 Effect of dietary agents on Notch pathway components in vivo by cancer type. 
*indicates use of dietary analog, #indicates alternate delivery method e.g. nanoparticle. 
Dietary Agent Cancer Type Observations References 
Curcumin Colorectal# ↓ NICD-1, Ki67 (159) 
  ↑ cleaved Caspase 3 
  ↓ tumor volume; additive effect on tumor volume with oxaliplatin 
 Pancreatic ↓ Notch-1, Epithelial Cell Adhesion Molecule, Nanog 
(158) 
  ↓ tumor volume 
Genistein Breast ↓ Notch-1, Cyclin D1 (194) 
 Prostate ↓ Notch-1, p-Akt, FoxM1 (173) 
  ↓ tumor volume 
Honokiol Colorectal ↓ NICD-1, Jagged-1, Hes-1, Presenilin-1, Nicastrin 
(195) 
  ↓ tumor volume 
Sulforaphane Prostate ↑ NICD-2 (190) 
Vitamin D Ovarian* ↓ Notch signaling pathway (196) 
  ↑ DNA fragmentation 





cytosolic NF-κB inhibitor IκBα in lymphoma cells, suggesting NF-κB pathway 
deactivation (153).  The putative NF-κB deactivation downstream of Notch is one 
mechanism by which curcumin may diminish proliferation and enhances apoptosis in 
cancer cells. 
In addition to NF-κB, curcumin inhibits the JAK/STAT signaling pathway.  
Nanoparticle-delivered curcumin treatment of glioblastoma and medulloblastoma cell 
lines reduced activating STAT3 phosphorylation at tyrosine 705 (162).  The same effect 
was observed in isolated ALDH+/CD133+ colon CSCs following treatment with the 
curcumin analog FLLL32 (160).  Given the roles of both NF-κB and JAK/STAT in 
cancer progression, targeting these pathways either directly or secondary to Notch 





Curcumin reduces invasiveness and CSC properties in several cell models of cancer.  
Curcumin treatment inhibited invasion of oral carcinoma and osteosarcoma cells, and in 
osteosarcoma this effect was reversed by ectopic Notch-1 expression (154,156).  Matrix 
metalloprotease-9 was down-regulated by curcumin treatment in osteosarcoma, oral 
carcinoma, and pancreatic cancer cells (154,156,158).  Curcumin and its analogs inhibit 
the size and number of tumorspheres formed in colon, pancreatic, and esophageal cancer 
cells, suggesting inhibition of the CSC population by curcumin (155,158–160).  
Oxaliplatin treatment of colorectal cancer cells enhanced ALDH activity and this effect 
was countered by curcumin (159).  Similarly, nanoparticle-delivered curcumin reduced 
the CD133+ CSC fraction in medulloblastoma and glioblastoma cell lines (162).  
Collectively, the results suggest that curcumin may have clinical application in 
preventing invasion and metastasis of primary tumors, as well as tumor recurrence related 
to CSCs.   
 
2.3.2 Genistein 
Studies examining the efficacy of genistein, an isoflavone found in soy, 
demonstrate consistent Notch inhibition across multiple types of cancer (Figure 2.1, 
Table 2.1).  Use of genistein to target Notch has been particularly well studied in 
pancreatic cancer cell lines, although cell models of neuroblastoma, prostate, and breast 
cancer have also been reported.  Treatment with genistein up-regulated the Notch 
inhibitor miR-34a in pancreatic cancer cells and suppressed Notch-1 (168).  Both Notch-
1 mRNA and protein (166–173) are suppressed by genistein treatment in vitro, 





of Notch-1.  The Notch downstream target Hes-1 is also suppressed by genistein in 
cultured pancreatic cancer and neuroblastoma cell lines (167,169,170).  Importantly, 
Notch-1 siRNA and over-expression of Notch-1 by viral transduction respectively 
augmented and attenuated the effects of genistein on growth of cultured pancreatic and 
prostate cancer cell lines, underscoring the critical role of Notch signaling in cell viability 
(169,170,173).  In a xenograft model of prostate cancer utilizing SCID mice, genistein 
administered either through dietary incorporation or by gavage reduced Notch-1, 
phosphorylated Akt, and FoxM1 proteins, and reduced tumor growth relative to untreated 
animals (Table 2.2) (173).  The results support use of genistein as an anticancer agent and 
are consistent with the in vitro data for its inhibitory role against Notch and overall cell 
survival.   
One model examining the efficacy of genistein in breast cancer prevention 
followed female rats fed lifelong diets containing one of the following as the sole protein 
source:  soy protein isolate, casein, or casein supplemented with genistein (Table 2.2) 
(194).  Mammary epithelial cells, which give rise to mammary tumors, isolated from rats 
upon sacrifice at post-natal day 50 fed either the soy protein isolate or the supplemented 
diet had reduced expression of Notch-2 mRNA compared to rats fed casein alone.  The 
supplemented diet had no effect on Hes-1 mRNA expression, but cyclin D1 protein 
staining was induced relative to casein alone.  Interestingly, soy protein isolate-fed rats 
exhibited higher levels of Hes-1 mRNA compared to casein-fed rats, which may indicate 
Notch activation via a different Notch receptor (194).  The results indicate that orally 
administered genistein inhibits Notch-2 mRNA in cancer-free rats, although it cannot be 





Similar to curcumin, genistein treatment reduced NF-κB binding activity in 
pancreatic cancer cells (169–171).  Notch-1 overexpressing AsPC-1 pancreatic cancer 
cells had increased p65 expression compared to control-transfected cells, and this 
increase was attenuated by genistein in a dose-dependent manner (172).  A decrease in 
p65 protein was also observed in SH-SY5Y and SK-N-BE2 neuroblastoma cells 
following genistein treatment (167).  The observed decrease in Notch and NF-κB 
expression occurred concomitantly with cell cycle arrest, apoptosis, and reduced 
proliferation in cancer cells (167,169–172). 
Genistein blocks EMT-related proteins, including ZEB1, ZEB2, Snail2, and 
Vimentin, and induces E-cadherin in pancreatic cancer cells (172).  Decreased migration 
was observed in an in vitro wound healing assay in pancreatic cancer cells after genistein 
treatment, suggesting that genistein reverses EMT (172).  Genistein also inhibits matrix 
metalloproteases-2 and -9, epidermal growth factor receptor (EGFR), vascular 
endothelial growth factor, and basic-fibroblast growth factor in a neuroblastoma cell 
model (167).  In AsPC-1 pancreatic cancer cells, overexpression of Notch-1 increased 
sphere formation; treatment with genistein suppressed sphere formation in both control- 
and Notch-transfected cells, suggesting that genistein can attenuate Notch-1 mediated 
sphere formation (172).  The results indicate that genistein can reverse EMT and inhibit 
CSCs in vitro. 
 
2.3.3 EGCG and Tea Polyphenols 
Epigallocatechin-3-gallate (EGCG) and green tea extract modulate expression of 





and SH-SY5Y neuroblastoma cell lines (165).  Similarly, EGCG suppressed Notch-1 in 
CSCs isolated from head and neck squamous cell carcinoma surgical specimens and 
Notch-2 in cultured colon cancer cell lines (163,164).  Pre-treatment of head and neck 
CSCs with cisplatin (10 μM) either alone or in combination with EGCG (5 μM) prior to 
grafting resulted in decreased tumor growth in both models, and the effect was strongest 
with co-treatment (164).  EGCG treatment nearly ablated Hes-1 gene expression in colon 
cancer cell lines, suggesting pathway deactivation (163).  Oral administration of EGCG 
to HT-29 colon cancer cell-xenograft nude mice decreased tumor growth at all doses (5, 
10, or 20 mg/kg/d), in a dose-independent manner (163).  Theaflavin-3,3’-digallate (TF3) 
is an analog of EGCG generated from its polymerization and oxidation and is shown to 
have bioactivity against ovarian cancer cells (197).  TF3 treatment of OVCAR-3 cells 
reduced expression of NICD-1 (197). 
EGCG treatment induced Notch-4 expression in squamous cell carcinoma of the 
tongue cell lines SCC-25 and Cal-27, although this effect varied by EGCG incubation 
time and cell line (198).  While EGCG and green tea extract both induced cell cycle 
arrest in SCC-25 and Cal-27 cells, it is unclear if this effect was mediated by Notch 
signaling or by some other mechanism (198).  In neuroblastoma N2A cells transfected 
with mutated amyloid precursor protein, EGCG induced expression of the active 
fragment of ADAM10 protein, which corresponded with increased levels of soluble 
amyloid precursor protein (199).  Further research on the role of EGCG in ADAM10 
modulation in several malignancies is needed. 
EGCG and its related compounds modulate Notch-related pathways and processes, 





Myc, hypoxia-inducible factor 1α, and vascular endothelial growth factor in ovarian 
cancer cells (197).  Inhibition of c-Myc, hypoxia-inducible factor 1α, and vascular 
endothelial growth factor by TF3 was reversed by ectopic expression of NICD-1, 
suggesting a critical role of Notch pathway in angiogenesis that is modifiable by TF3 
(197).  EGCG treatment of neuroblastoma cell lines induced expression of E-cadherin, 
suggesting a shift towards an epithelial cell phenotype (165).  Proteins which contribute 
to cancer cell invasiveness such as matrix metalloproteases-2 and -9 were also suppressed 
following EGCG treatment (165).  EGCG-mediated Notch inhibition reduced sphere 
formation in head and neck carcinoma cells, and this effect was augmented by the 
addition of cisplatin (164), suggesting a beneficial role of EGCG in addition to 
conventional anticancer drugs.  Taken together, the data support inhibition of Notch 
receptors and activity by EGCG in vitro, as well as a role for EGCG in reducing markers 
of an aggressive cancer phenotype. 
 
2.3.4 Resveratrol 
Studies of resveratrol, the stilbene found in the skins of grapes, blueberries, and 
peanuts, underscore the context-dependent nature of Notch signaling as both oncogenic 
and tumor suppressive (Table 2.1).  Several studies examining the role of resveratrol on 
modulation of Notch signaling show a dichotomy of evidence regarding the specific 
effect of resveratrol on Notch pathway components and the biological significance of 
their modulation. 
Accumulating evidence suggests that select cancer types, including neuroendocrine 





suppression (200).  Resveratrol induced Notch-1 and Notch-2 expression in 
neuroendocrine tumors (178,183,201).  Resveratrol reduced tumor volume in xenograft 
animal models using pulmonary carcinoid or anaplastic thyroid carcinoma cells (178,201).  
Daily injections of 5 mg/kg/d or 2 mg/animal/d decreased tumor growth in NCI-H727 
and HTh7 xenograft tumors, respectively (178,201).  A similar effect was observed when 
resveratrol was administered to NCI-H727 nude mice by oral gavage (201).   
Resveratrol activates Notch in glioblastoma and medulloblastoma (179,180).  The 
biological significance of Notch activity in brain tumors is currently unclear and may be 
dependent on specific receptor activation, although some research suggests that Notch 
activation has a tumor suppressive function (202).  Resveratrol treatment reduces 
medulloblastoma cell survival (180).  However, addition of  L-685,458 (a GSI, hereafter 
referred to as GSI-L) did not reduce cell survival, suggesting that induction of Notch by 
resveratrol does not play a causal role in reducing medulloblastoma cell viability (180).  
In glioblastoma cells, however, the GSI MRK-003 reduced resveratrol-mediated 
inhibition of proliferation, supporting a tumor suppressive role of Notch in glioblastoma 
(179).  
Resveratrol suppresses Notch in cell models of T-cell acute lymphoblastic 
leukemia, cervical, ovarian, and breast cancer (176,177,181,182).  In ovarian and cervical 
cancer, however, addition of GSI-L caused a decrease in Hes-1 protein expression 
without altering viability, suggesting that Notch inhibition is dispensable to cancer cell 
death (177,181).  In highly invasive MCFCA1a and lowly invasive MCFCA1h breast 
cancer cells, resveratrol enhanced binding of DNA methyl transferase-3B to the 





silencing (176).  Resveratrol reduced expression of Hes-1 and Hey-1 in MCFCA1a and 
MCFCA1h cells (176), suggesting  pathway deactivation.  Collectively, these studies 
continue to highlight the context-dependent nature of Notch signaling by resveratrol and 
the differential effect of pathway activation by cell type.  
 
2.3.5 Retinoic Acid 
Retinoic acid and its related compounds, collectively referred to as retinoids, inhibit 
Notch expression and signaling in cultured cancer cells (Figure 2.1, Table 2.1).  All-trans 
retinoic acid (ATRA) reduced Notch-1 expression in glioblastoma and ovarian cancer, 
and NICD-1 expression was blocked in the glioblastoma model, suggesting pathway 
deactivation (185,187).  In breast cancer, ATRA suppressed Notch-3 protein in MDA-
MB-231 cells, although was reported to have no effect on Notch-1 or NICD-1 in SKBR3 
breast cancer cells (203,204).  In contrast, coupling ATRA with somatostatin and 
melatonin had an inhibitory effect on Notch-1 and NICD-1 in MCF-7 breast cancer cells 
(184).  It is unclear whether these differences are cell line-specific, or a result of varying 
treatment methods.  Treatment with retinoids, including fenretinide (4-
hydroxy(pheyl)retinamide, 4-HPR) and the adamantyl-substituted compounds (E)-4-[3-
(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid  (Cl-AHPC) and (E)-3-{2-[3-(1-
adamantyl)-4-hydroxyphenyl]-5-pyrimidinyl}-2-propenoic acid (AHP3) inhibited Notch-
1 in neuroblastoma (186) and pancreatic cancer cell lines (188). 
ATRA treatment suppressed migration and invasion of ovarian cancer cells in 
Transwell chamber assays (187).  The retinoid 4-HPR induced E-cadherin, supporting a 





treated with 13-cis retinoic acid displayed increased migration compared to untreated 
cells in a wound assay (205).  The increase in migration was not attenuated by treatment 
with the GSI DAPT, suggesting Notch-independent induction of cell migration (205).  
Interestingly, treatment of neuroblastoma cells with 13-cis retinoic acid still induced cell 
cycle arrest and increased the fraction of Annexin V positive cells (205).  
Historically, ATRA has been used as a differentiation-inducing agent (206).  
Intuitively, treatment with ATRA reduced sphere size and formation in glioblastoma and 
ovarian cancer cells (185,187).  Pre-treating glioblastoma and ovarian cancer cells with 
ATRA prior to grafting impaired tumor formation in both models, suggesting that ATRA 
reduces the tumorigenic capacity of cancer cells (185,187).  Furthermore, in a 
glioblastoma xenograft model, dissociated ATRA-treated tumors displayed reduced 
sphere formation when cultured ex vivo compared to untreated dissociated tumor cells 
(185).  The retinoids Cl-AHPC and AHP3 also blocked sphere formation in pancreatic 
cancer cells (188).  ATRA-treated tumor cells in the ovarian cancer model displayed 
decreased ALDH-1 expression (187).  These data support an anti-CSC role for ATRA in 




Sulforaphane, a dietary agent released from cruciferous vegetables such as broccoli 
and broccoli sprouts after processing or chewing, is well studied in the field of cancer.  
Sulforaphane down-regulates full-length Notch-1, -2, and -4 proteins in prostate cancer 





treatment mediates cleavage of Notch receptors (Table 2.1) (190).  Hes-1 reporter activity 
was induced by sulforaphane in LNCaP and PC-3 cells suggesting pathway activation 
(190).  In contrast to the NICD-2 induction seen in LNCaP cells treated with 
sulforaphane in vitro, tumor tissue from transgenic adenocarcinoma mouse prostate mice 
treated with sulforaphane had reduced NICD-2 (190) (Table 2.2).  While two studies 
have shown that sulforaphane treatment inhibits prostate cancer cell migration and 
expression of EMT-related proteins, this effect was Notch-independent (190,191), 
suggesting that sulforaphane reduces cell migration through alternative mechanisms.   
Sulforaphane inhibited Notch-1 in pancreatic cancer cells, although expression of 
other Notch receptors was not described (189).  Interestingly, sulforaphane treatment 
negated a gemcitabine-induced rise in Notch-1 expression in MiaPaCa2 cells (189).  Co-
treatment of MiaPaCa2 cells with sulforaphane and gemcitabine more strongly reduced 
cell viability compared to use of either agent alone (189).  The results suggest that 
sulforaphane may enhance the effect of anticancer drugs in pancreatic cancer.  In vivo, 
sulforaphane effectively inhibited tumor growth in mice when MiaPaCa2 cells were pre-
treated with the agent before grafting, and when the agent was administered by i.p. 
injection following inoculation (189).  The combination of sulforaphane and gemcitabine 
in vivo, however, reduced animal body weight by approximately 15% (189).  Further 
studies are required to determine the effect of sulforaphane on Notch in in vivo models of 






2.3.7 Vitamin D 
Results regarding the efficacy of vitamin D as a Notch modulator are mixed.  Two 
reports show that 1,25-dihydroxyvitamin D3 treatment has no effect on Notch-2, Notch-4, 
or Jagged-1 protein expression in a cell model of glioblastoma, or on Notch-1 or Jagged-
1 in keratinocytes (207,208).  In contrast, a similar dose of 1,25-dihydroxyvitamin D3 
suppresses Notch target genes in spontaneously immortalized, non-malignant prostate 
cells (209).  In the MCF10DCIS.com breast cancer cell line, treatment with the Gemini 
vitamin D analog BXL0124 blocked Notch-1 activation and expression of Jagged-1, -2, 
and DLL-1 (Table 2.1) (92).  Interestingly, in the MCF10DCIS.com model, BXL0124 
rapidly induced message and protein expression of Hes-1 (92).  Knock-down of Hes-1 
with siRNA partially reversed the BXL0124-mediated suppression of NICD-1, Jagged-2, 
and c-Myc protein.  Conversely, Hes-1 overexpression in the absence of BXL0124 
suppressed NICD-1, Jagged-2, and c-Myc, suggesting a negative feedback loop in which 
Hes-1 inhibits Notch activation (92).  Tumor tissue from SKOV-3 xenograft nude mice 
i.p. treated with the vitamin D analog MT19c had decreased expression of Notch pathway 
components, and increased DNA fragmentation relative to control (Table 2.2) (196).  
More data is needed on the role of vitamin D and its analogs on Notch modulation across 
several types of cancer. 
 
2.3.8 Other Agents 
Treatment of non-small cell lung cancer cells with delta-tocotrienol, a form of 
vitamin E, increased miR-34a expression and decreased expression of Notch-1 and 





with apoptosis and reduced cell migration, and this effect was further enhanced by co-
treatment with cisplatin in vitro (211,212). 
Honokiol, a traditional Chinese and Japanese herbal therapeutic, inhibited Notch 
components, including Notch-1 and -2, Jagged-1, Hes-1, and subunits of the gamma 
secretase complex in melanoma and colon cancer cells (195,213,214).  In addition, sphere 
formation and cell survival were inhibited by honokiol treatment either alone or in 
combination with a single dose of ionizing radiation at 5 Gy (195,214).  The additive 
effect of honokiol and radiation was confirmed in nude mice xenografted with HCT116 
cells.  Tumor mass along with expression of CSC- and Notch-related proteins were 
inhibited by the co-treatment in vivo (Table 2.2) (195), congruent with the reported effect 
of honokiol in vitro.  
Withaferin A, a lactone found in the leaves of Withania somnifera (Indian Winter 
cherry) has been used as part of traditional Indian medicine for several years and inhibits 
angiogenesis and cell proliferation (215,216).  In breast cancer cells, Withaferin A 
treatment suppressed NICD-1 and induced NICD-2 and NICD-4 expression (217).  The 
net effect was an increase in RBP-Jκ and Hes-1 promoter activity, and reduced migration 
and cell viability (217).  Knock-down of Notch-2, but not Notch-4, in these experiments 
further decreased migration and proliferation in breast cancer cells.  Taken together, 
activation of Notch-2 by Withaferin A appears unfavorable, but the total effect of 
Withaferin A treatment on breast cancer cells is beneficial.  In a follow-up study, RNA 
interference against Notch-4 did not significantly contribute to Withaferin A-induced 
suppression of ALDH1 activity, further identifying Notch-4 induction by Withaferin A as 





cell line-dependent effect, with treatment leading to inhibition of NICD-1 and NICD-3 in 
SKOV3 and CaOV3 cells, respectively (219).  NICD-1 is also inhibited by Withaferin A 
in colon cancer cell lines (220).  Importantly, viability of the normal colon cell line FHC 




The Notch signaling pathway is one of several pathways which influence 
development and progression of cancer.  It is particularly important to target Notch, in 
part, because of the pathway’s extensive degree of cross-communication with pathways 
including Wnt, NF-κB, and JAK/STAT, which collectively confer survival advantages to 
cancer cells (221).  In addition, Notch activation is critically involved in the maintenance 
of highly tumorigenic and treatment-resistant CSCs, which may play a role in tumor 
survival and recurrence (82). 
The studies detailed throughout this text highlight both the vast progress that has 
been made as well as gaps in our current understanding of the relationship between 
dietary agents and Notch.  It is clear that several dietary agents are capable of achieving 
substantial changes in expression of Notch components and pathway activity in vitro, 
which may contribute to cancer cell death.   
Curcumin and genistein have the highest strength of evidence supporting Notch-
mediated alterations in cancer cell survival.  The indispensable nature of Notch inhibition 
by curcumin and genistein, particularly in pancreatic cancer cells, confirms that this 





modifiable by curcumin and genistein in vitro and in vivo in models of pancreatic and 
prostate cancer, suggesting that these bioactives may be clinically relevant in the field of 
cancer (152,169,173).  A major challenge related to curcumin is its relatively poor 
bioavailability, although several strategies to improve the bioavailability of curcumin are 
undergoing active research (222). 
 Development of GSIs is a major focus in the field of Notch cancer biology.  
Recent research in cancer biology, however, has identified a role of the alpha secretases 
ADAM10 and ADAM17 in activation of Notch and alterations to cell migration and 
invasion (64,223,224).  While each of these genes is required for Notch activation, the 
role of dietary agents in modulating ADAM10 or ADAM17 in the context of cancer is 
unexplored (225).  Discovery of dietary or natural agents which suppress ADAM10 or 
ADAM17 specifically in cancer cells will have implications for modulation of not only 
Notch signaling, but also EGFR signaling and cell migration (226). 
In conclusion, Notch signaling plays a critical role in cancer cell proliferation and 
survival.  Use of dietary agents such as curcumin and genistein is a novel method of 
inhibiting Notch in cancer cells which may result in chemopreventive or anticancer 
effects, with low toxicity to normal tissue.  Future studies examining the role of dietary 
agents in modulation of Notch will further our understanding of Notch biology and 





CHAPTER 3. DIALLYL TRISULFIDE MODULATES NOTCH PATHWAY 
COMPONENTS IN BREAST CANCER CELLS 
3.1 Introduction 
Breast cancer is the most frequently diagnosed cancer among US women (1).  
Widespread use of mammography has greatly improved early detection of breast 
cancer; however, blocking progression to invasive breast cancer remains a clinical 
challenge (1,5).  Epidemiological data show an inverse relationship between 
consumption of Allium vegetables, including garlic and onions, and development of 
several types of cancer (17–19).  Specifically, a case-control study in France 
examining development of breast cancer reported an odds-ratio of 0.25 (95%CI: 0.11- 
0.55) among women consuming 11-12 weekly servings of garlic and onions 
compared to women consuming fewer than 7 weekly servings (17). 
Multiple reports indicate that DATS is a more potent inhibitor of cancer cell 
survival compared to its analogs diallyl disulfide or diallyl sulfide (227,228).  MCF-7 
xenograft mice treated with 5 μmol DATS/kg body weight had significantly smaller 
tumors compared to control-treated animals (227).  SUM159 xenograft mice treated 
with DATS starting on date of implantation had reduced tumor incidence and tumor 
weight compared to control-treated animals (34).  Tumor tissue from DATS-treated 
SUM159 xenograft mice also displayed reduced ALDH1 activity compared to tissue 





DATS treatment does not reduce body weight in xenograft models indicating that 
DATS is not toxic to major organs (33,34). 
Several mechanisms of action of DATS in cancer cells have been identified in 
vitro.  Treating cancer cells with DATS mediates production of reactive oxygen 
species and induces apoptosis (39).  Overexpression of superoxide dismutase or 
addition of the antioxidant N-acetylcysteine attenuates the effect of DATS treatment 
on apoptosis in cancer cells (39,227).  DATS-mediated apoptosis is also attenuated by 
the JNK-inhibitor SP600125 (227).  Importantly, DATS induces apoptosis in both 
triple-negative and ER-positive breast cancer cells (39,227,228).   DATS treatment in 
breast cancer cells inhibits cell migration, invasion, and mammosphere formation 
(46,34).  In osteosarcoma cells, DATS suppressed protein expression of the Notch 
pathway components Notch-1 and Hes-1, and the Notch downstream target cyclin D1 
(47). 
Notch signaling is activated in breast cancer cells compared to normal tissue 
and plays a role in cell proliferation and differentiation (54,58).  Cells with high 
levels of active Notch signaling display increased tumorigenic capacity in vivo, and 
Notch contributes to CSC maintenance (124).  Notch is a juxtacrine signaling 
pathway in which membrane-bound Notch ligands activate Notch receptors on 
neighboring cells.  Notch ligands, including Jagged-1, Jagged-2, DLL-1, -3, and -4, 
bind to Notch receptors (Notch-1, -2, -3, -4), inducing a change in receptor 
conformation and permitting cleavage of the Notch extracellular domain.  Cleavage 
of Notch extracellular domain is achieved by ADAM10 in a ligand-dependent fashion.  





cleave NICD.  NICD translocates to the nucleus where it binds RBP-Jκ and recruits 
the co-activator mastermind-like, thereby activating transcription.  Downstream 
targets of the Notch pathway include canonical targets Hes and Hey as well as several 
context-dependent targets such as cyclin D1, c-myc, and Nanog (50).  
Ligand binding is the first critical step of Notch activation in the canonical 
pathway.  Importantly, expression of the Notch ligands Jagged-1 and Jagged-2 is 
increased in invasive ductal carcinoma compared to benign breast tissue (58).  In 
addition, overexpression of Jagged-1 in tumor tissue was observed in 78% of patients 
with invasive breast cancer, suggesting that Jagged-1 activation is frequently 
observed in breast cancer (59).  High tumor expression of Jagged-1 and Jagged-2 is 
associated with reduced survival and increased probability of relapse (60–62).  Notch 
ligands therefore represent a potential therapeutic target for Notch inhibition in cancer. 
Following Notch ligand binding, cleavage of Notch extracellular domain is 
achieved by ADAM proteins.  ADAMs are a broad family of proteases responsible 
for cleavage of several substrates relevant to cancer progression, including Notch 
(225).  ADAM proteins are first synthesized as zymogens and are processed by 
proprotein convertase-7 and furin at the Golgi to yield active proteases (74).  After 
processing, active ADAM10 and ADAM17 translocate to the cell membrane where 
they cleave the extracellular domains of target substrates, including Notch-1.  
ADAM10 constitutively cleaves Notch upon ligand binding, and ADAM17 is capable 
of cleaving Notch under ligand-independent conditions (86,87).  In addition, 
ADAM10 cleaves the cell-cell adhesion protein E-cadherin and HER2, while 





Expression of tumor ADAM10 and ADAM17 is inversely associated with survival in 
several types of cancers, including breast cancer (224).   
The Notch signaling pathway has emerged as a therapeutic target in cancer.  
The gamma secretase complex is a common target for Notch inhibition in cancer 
patients; however use of GSIs in clinical trials has revealed unacceptable 
gastrointestinal side effects, nausea, and vomiting (229,230).  Development of alpha 
secretase inhibitors is underway.  Early phase clinical trials of small molecule 
inhibitors against ADAM10 and ADAM17 have shown some promise in HER2+ 
breast cancer patients (231), although previous use of ADAM17 inhibitors for 
treatment of rheumatoid arthritis resulted in hepatotoxicity (232).   
The hypothesis of the present study is that DATS inhibits Notch signaling 
pathway in breast cancer cells.  We report a novel mechanism of action of DATS by 
targeting alpha secretases and Notch ligands in breast cancer cells.  Furthermore, we 
show with a clonogenic assay that DATS has a long-lasting effect on breast cancer 
cells.  We conclude that DATS targets components of the Notch signaling pathway, 
including ADAM10, ADAM17, Jagged-1, and Jagged-2 in breast cancer cells. 
 
3.2 Materials and Methods 
Cell Culture and Reagents 
Human breast cancer cell lines MDA-MB-231 and MCF-7 were purchased 
from American Type Culture Collection (ATCC, Manassas VA).  MDA-MB-231 
cells were derived from a 51 y old female patient with breast adenocarcinoma; the 





female patient with breast adenocarcinoma; the cells are ER-positive.  MDA-MB-231 
cells were cultured in RPMI1640 (Corning, Manassas VA) supplemented with 10% 
fetal bovine serum (FBS, Corning) and 1% penicillin/streptomycin antibiotic mixture 
(PS, Corning).  MCF-7 cells were cultured in Eagle’s Minimum Essential Medium 
(MEM, Corning) with 0.01 mg/ml human recombinant insulin (Sigma-Aldrich, St. 
Louis MO), 10% FBS, and 1% PS. 
MCF10A-H-Ras and MCF-12A cells were kind gifts from Dr. Dorothy 
Teegarden and Dr. Ignacio Camarillo, respectively, Purdue University.  
Characteristics of the MCF10A-H-Ras cell line are well described in the literature and 
have recently been reviewed (233).  Briefly, the MCF10A-H-Ras cell line is a 
modified version of normal-like MCF-10A breast epithelial cells, with a T24-mutated 
Harvey-ras stable gene insertion.  These cells are capable of forming ducts in vivo, 
and will sometimes progress to invasive ductal carcinoma (233).  MCF-12A cells 
were derived from a 60 y old  Caucasian female with fibrocystic breast disease; the 
cells are non-tumorigenic in vivo and serve as a model of normal-like breast tissue  
(234).  Both cell lines were cultured in Dulbecco’s Modification of Eagle’s Medium 
(DMEM)/Ham’s F-12 50/50 Mix (Corning), supplemented with 20 ng/ml human 
recombinant EGF (StemCell Technologies, Vancouver BC), 100 ng/ml cholera toxin 
(Calbiochem, Billerica MA), 0.01 mg/ml human recombinant insulin, 500 ng/ml 
hydrocortisone (Sigma-Aldrich), 5% donor horse serum (Corning), and 1% PS.  All 
cells were regularly maintained at 37ºC with 5% carbon dioxide. 
Diallyl trisulfide (DATS, ≥ 98% purity) was purchased from LKT Laboratories 





Corning.  Trypan blue was purchased from Mediatech (Manassas, VA) and crystal 
violet was purchased from Amresco (Boise, ID).  ADAM10 (14194), ADAM17 
(6978), Jagged-1 (2155), and Jagged-2 (2210) antibodies were purchased from Cell 
Signaling (Danvers, MA) and Actin (A5441) was purchased from Sigma-Aldrich. 
 
Trypan Blue Exclusion Assay 
 Cells were seeded into 12-well plates at a density of 10,000 cells/well for 
MDA-MB-231 cells or 50,000 cells/well for MCF-7, MCF10A-H-Ras, and MCF-12A 
cells and allowed to attach for 24 h.  Cell culture medium was then replaced with 
medium containing DATS (20, 40, 60, 80, 100 μmol/L) or vehicle control (DMSO, 
<0.55% v/v).  Cells were incubated with DATS for 24 h.  Cells were counted in 30 
μL trypan blue under a hemocytometer. 
 
Clonogenic Assay 
MDA-MB-231 and MCF-7 breast cancer cells (1x106) were plated in 100 mm 
plates and allowed to attach for 24 h.  Cells were then treated for 24 h with 20, 40, or 
60 µmol/L DATS or control (DMSO, <0.4% v/v).  After 24 h of DATS treatment, 
cells were reseeded into 6 well plates with 300 cells/well and incubated in the absence 
of DATS.  MDA-MB-231 cells were incubated for 10 d in the absence of DATS, and 
MCF-7 cells were incubated 14 d.  Growth medium was changed every 3 d.  Colonies 








Cells were treated with 20, 40, or 60 µmol/L DATS or control (DMSO) for 16 
or 24 h.  Protein levels were first determined with Bradford reagent.  Equal amounts 
of protein were then separated on polyacrylamide gels and transferred to PVDF 
membranes.  Membranes were incubated in primary antibody overnight at 4ºC with 
gentle rocking and developed with ECL Prime Detection Reagent (GE Amersham, 
Batavia, IL).  Band quantification was completed with UN-SCAN-IT software (Silk 
Scientific, Orem, UT). 
 
qRT-PCR 
Cells were treated with 20, 40, or 60 µmol/L DATS or control (DMSO) for 24 h.  
Cellular RNA was isolated using PureLink RNA Mini Kit and PureLink DNase Kit 
(Invitrogen, Carlsbad CA), and 2 µg of RNA were converted to cDNA using the 
BioRad iScript cDNA Synthesis Kit (BioRad, Hercules, CA).  PCR was performed on 
80 ng of cDNA using SYBR Green I Master Mix (Roche, Indianapolis, IN) and the 
following primers:  ADAM10 (forward GTAGTAATCCAAAGTTGCCTCCT, 
reverse CAGTTAGCGTCTCATGTGTCC), GAPDH (forward 
GGAGCGAGATCCCTCCAAAAT, reverse GGCTCTTCTCATACTTCTCATGG).  
Primers were purchased from Integrated DNA Technologies (IDT, Coralville, IA).  
PCR was carried out using a LightCycler 96 system (Roche) under the following 
parameters:  10 minutes at 95ºC; 45 cycles of 15 seconds at 95ºC, 10 seconds at 60ºC, 
and 30 seconds at 72ºC; 10 seconds at 95ºC, 60 seconds at 65ºC, and 1 second at 97ºC.  






All statistical analysis was completed using GraphPad Prism 6.0 software (La 
Jolla, CA).  Trypan blue assay and Western blotting densitometry were analyzed by 
one-way ANOVA followed by Dunnett’s multiple comparisons to determine 
differences between groups.  Clonogenic assay and qRT-PCR data were analyzed by 
unpaired t-test to determine differences between groups.  P-values < 0.05 were 
considered significant.  
 
3.3 Results 
Diallyl Trisulfide Reduces Viability of Breast Cancer Cells 
We first examined the ability of DATS to inhibit viability of cultured breast 
cancer cell lines.  Cells were treated with DATS (20, 40, 60, 80, 100 μmol/L) or 
control (DMSO) and viability was determined after 24 h using trypan blue exclusion 
assay.  Treatment with 40 μmol/L DATS reduced cell viability by approximately 53% 
in MDA-MB-231 and MCF-7 breast cancer cells, indicating that the IC50 value of 
DATS is near 40 μmol/L (Figures 3.1A and 3.1B).  Treatment of MCF10A-H-Ras 
cells with 40 μmol/L DATS reduced viability by 50% (Figure 3.1C).  In contrast, 
treatment of the normal-like breast epithelial cell line MCF-12A with 40 μmol/L 
DATS reduced viability by only approximately 19% (Figure 3.1D).  Furthermore, 
treatment of MCF-12A cells with up to 100 μmol/L DATS reduced viability by 46%, 
suggesting that the IC50 value of DATS in normal breast tissue is higher than that of 







Figure 3.1 Effect of DATS on viability in breast cancer cells and normal-like breast 
epithelial cells. 
MDA-MB-231 (A), MCF-7 (B), MCF10A-H-Ras (C), and MCF-12A (D) cells were 
treated with increasing doses of DATS for 24 h.  Data points, mean (n=2); bars, SEM 
of two independent experiments, each performed in triplicate.  *, P < 0.05 in 
comparison with control-treated cells, by one-way ANOVA followed by Dunnett’s 
multiple comparisons test. 
 
Diallyl Trisulfide Inhibits Colony Formation in Human Breast Cancer Cell Lines 
We next sought to determine if DATS could inhibit colony formation in breast 
cancer cells.  Breast cancer cells were treated with DATS (20, 40, 60 μmol/L) or 
control for 24 h, reseeded at equal cell densities, and incubated 10-14 d in the absence 
of DATS. Treatment with DATS resulted in a dose-dependent decrease in the number 







Figure 3.2 DATS inhibits colony formation in MDA-MB-231 and MCF-7 breast 
cancer cells. 
Representative wells from MDA-MB-231 (A) and MCF-7 (B) breast cancer cells.  
Quantification of colony formation in MDA-MB-231 (C) and MCF-7 (D) breast 
cancer cells.  Columns, mean (n=2); bars, SEM of two independent experiments, each 
performed in triplicate.  *, P < 0.05 in comparison with control-treated cells, by 
unpaired student’s t-test. 
 
inhibited by approximately 47 and 64% after 60 μmol/L DATS treatment in MDA-
MB-231 and MCF-7 cells, respectively. 
 
Diallyl Trisulfide Inhibits Alpha Secretase Protein Expression 
Alpha secretases, including ADAM10 and ADAM17, are required for cleavage 
of membrane-bound proteins relevant to breast cancer progression, including Notch 
receptor (226).  We tested the ability of DATS to inhibit alpha secretase proteins in 






Figure 3.3 Effect of DATS on ADAM10 protein in breast cancer cells at 16 h 
treatment. 
Representative Western blots of ADAM10 in MDA-MB-231 (A) and MCF-7 (B) 
cells after 16 h of DATS treatment.  Densitometry analysis of ADAM10 precursor 
expression (C) and active ADAM10 expression (D).  Columns, mean (n=2); bars, 
SEM of two independent experiments.  *, P < 0.05 by one-way ANOVA followed by 
Dunnett’s multiple comparisons test. 
 
synthesized as a 90 kDa zymogen which is subsequently cleaved by proprotein 
convertase-7/furin to yield a 68 kDa active protein (74).  DATS treatment down-
regulated ADAM10 precursor (90 kDa) after 16 h of treatment in MDA-MB-231 
breast cancer cells (Figure 3.3A).  Active ADAM10 was not affected after 16 h of 






Figure 3.4 DATS inhibits ADAM10 precursor and active ADAM10 protein in breast 
cancer cells at 24 h treatment. 
Representative Western blots of ADAM10 in MDA-MB-231 (A), MCF-7 (B), and 
MCF10A-H-Ras cells (C) after 24 h of DATS treatment.  Densitometry analysis of 
ADAM10 precursor expression (D) and active ADAM10 expression (E).  Columns, 
mean (n=2); bars, SEM of two independent experiments.  *, P < 0.05 by one-way 
ANOVA followed by Dunnett’s multiple comparisons test. 
 
ADAM10 precursor was inhibited by approximately 40% in MDA-MB-231 and 
MCF-7 breast cancer cells (Figure 3.4A and 3.4B); and active ADAM10 was 
suppressed by approximately 80% in MDA-MB-231 and 70% in MCF10A-H-Ras 
cells (Figure 3.4A and 3.4C).  ADAM17 expression was reduced by DATS in MDA-
MB-231, MCF-7, and MCF10A-H-Ras cells after 24 h treatment (Figure 3.5).  
Collectively, the results support that DATS inhibits alpha secretase expression in 







Figure 3.5 DATS inhibits ADAM17 protein in breast cancer cells and H-Ras 
transformed breast epithelial cells. 
Representative Western blots of ADAM17 in MDA-MB-231 (A), MCF-7 (B), and 
MCF10A-H-Ras cells (C) after 24 h of DATS treatment.  Densitometry analysis of 
ADAM17 expression (D).  Columns, mean (n=3 in MDA-MB-231, n=2 in MCF-7 
and MCF10A-H-Ras); bars, SEM of two or three independent experiments.  *, P < 
0.05 by one-way ANOVA followed by Dunnett’s multiple comparisons test. 
 
Effect of DATS on ADAM10 mRNA in Breast Cancer Cells 
To elucidate a potential mechanism by which DATS inhibits ADAM10 protein 
expression, we performed qRT-PCR on MDA-MB-231 and MCF-7 breast cancer 
cells treated with DATS for 24 h.  Expression of ADAM10 mRNA following 24 h of 
DATS treatment in MDA-MB-231 and MCF-7 breast cancer cells shows a non-






Figure 3.6 Effect of DATS on ADAM10 mRNA levels in breast cancer cells. 
qRT-PCR of ADAM10 in MDA-MB-231 (A) and MCF-7 (B) breast cancer cells.  
Columns, mean (n=2); bars, SEM of two independent experiments, each performed in 
triplicate.  *, P < 0.05 in comparison with control-treated cells, by unpaired student’s 
t-test.   
 
Diallyl Trisulfide Inhibits Notch Ligand Expression 
Elevated levels of the Notch ligand Jagged-1 are associated with increased 
metastatic potential and decreased survival in breast cancer patients (60).  We tested 
the ability of DATS to inhibit Jagged-1 and Jagged-2 protein expression in breast 
cancer cells and H-Ras transformed breast epithelial cells.  Twenty-four hours of 40 
μmol/L DATS treatment reduced expression of Jagged-1 by approximately 82% in 
MCF10A-H-Ras cells and Jagged-2 by 50% in MCF-7 cells, suggesting that DATS 
can target Notch ligands in breast cancer cells (Figure 3.7B and 3.7C). 
 
3.4 Discussion 
The results of the present study support a role for DATS in inhibition of Notch 
signaling pathway in breast cancer cells.  We first show that DATS treatment reduces 






Figure 3.7 DATS inhibits Jagged-1 and Jagged-2 protein in breast cancer cells and H-
Ras transformed breast epithelial cells. 
Representative Western blots of Jagged-1and Jagged-2 in MDA-MB-231 (A), MCF-7 
(B), and MCF10A-H-Ras (C) cells after 24 h of DATS treatment.  Densitometry 
analysis of Jagged-1 (D) and Jagged-2 expression (E).  Columns, mean (n=2); bars, 
SEM of two independent experiments.  *, P < 0.05 by one-way ANOVA followed by 
Dunnett’s multiple comparisons test. 
 
μmol/L.  This is in accordance with other studies that reported an IC50 value for  
DATS after 24 h of treatment between 20 and 40 μmol/L in MDA-MB-231 and 
MCF-7 cells (190,228).  Our work is the first to study the effect of DATS on viability 
of MCF10A-H-Ras cells.  We show that MCF10A-H-Ras cells are sensitive to DATS 
treatment, and have a similar IC50 value to that of breast cancer cells lines.  
Importantly, viability of the normal-like breast epithelial cell line MCF-12A was 
reduced by DATS to a lesser extent compared to breast cancer cell lines, suggesting 





study which showed that DATS did not affect viability of the normal-like breast 
epithelial cell line MCF-10A at similar concentrations (39). 
Furthermore, we used a clonogenic assay to demonstrate the longevity of 
DATS’s effect on cell viability.  In this assay, cells were treated with DATS for 24 h, 
reseeded at equal cell densities, and incubated for 10-14 days in the absence of further 
DATS treatment.  The initial DATS treatment reduced colony formation in MDA-
MB-231 and MCF-7 breast cancer cells by 47 and 64%, respectively.  The results 
collectively show that DATS reduces the viability and clonal capacity of cancer cells, 
and that DATS treatment has a lasting effect on breast cancer cell proliferation.  
We report a novel mechanism of DATS by targeting the alpha secretases 
ADAM10 and ADAM17 in breast cancer cells.  We show that 40 μmol/L DATS 
inhibits ADAM10 precursor expression by approximately 40% in MDA-MB-231 and 
MCF-7 breast cancer cells within 24 h.  Furthermore, 40 μmol/L DATS inhibits 
active ADAM10 in MDA-MB-231 cells by 80%.  In addition, 40 μmol/L DATS 
suppresses ADAM17 by approximately 42% in MDA-MB-231 and 78% in MCF-7 
breast cancer cells after 24 h of treatment.  ADAM10 plays a critical role in Notch 
pathway activation.  ADAM10 also cleaves other membrane-bound substrates 
relevant to cancer biology, including EGFR ligands pro-EGF and pro-betacellulin, as 
well as HER2 (235,236).  ADAM10 mRNA expression is higher in breast cancer 
tissue compared to surrounding normal tissue (63).  In addition, triple-negative and 
HER2+ breast cancer patients with high tumor ADAM10 expression demonstrate 
poorer survival compared to those with low expression levels (64,65).  Interestingly, 





trastuzumab monotherapy in HER2+ breast cancer patients, suggesting a role for 
ADAM10 in trastuzumab resistance (65).  The data suggest that ADAM10 expression 
is induced in malignant breast tissue, and that overexpression of ADAM10 has 
negative consequences for patient survival and possibly drug resistance. 
While ADAM10 is constitutively active in the Notch pathway, ADAM17 can 
also play a role in Notch cleavage.  ADAM17 preferentially cleaves the Notch 
receptor in ligand-independent contexts (87).  Such contexts are achieved in certain 
types of cancer, including T-cell acute lymphoblastic leukemia (78), where mutations 
in Notch extracellular domain permit its cleavage in the absence of activating Notch 
ligands (237).  Notch fusion genes affecting the extracellular domain have been 
identified in cultured HC2218, HC1599, and HC1187 breast cancer cell lines (238).  
However, a later analysis of malignant breast tissue from Vietnamese and Mexican 
patients did not reveal mutations to Notch extracellular domain (239).  The 
prevalence of Notch extracellular domain mutations in breast cancer is thus 
controversial.  In breast cancer, ADAM17 protein expression in tumor tissue directly 
correlates with tumor grade and inversely correlates with overall survival (66).   
Our results are the first to demonstrate that DATS inhibits expression of the 
Notch ligands Jagged-1 and Jagged-2 in breast cancer cells.  Each of these ligands is 
implicated in activating the Notch pathway, and expression of each is inversely 
associated with survival in breast cancer (60,62).  Mutations in the Notch negative 
regulatory region identified in T-cell acute lymphoblastic leukemia permit ligand-
independent Notch activation, making Notch ligands in this type of cancer less 





region have not been conclusively identified (240), indicating that targeting Jagged-1 
and Jagged-2 is a clinically meaningful method of suppressing Notch signaling.  
These data collectively suggest that targeting Notch ligands as well as alpha 
secretases in breast cancer is critically important to prevent liberation of NICD and 
subsequent Notch pathway activation.  The results of our study suggest Notch 
pathway inhibition by DATS. Others have reported an inhibitory effect of DATS on 
Notch and Hes-1 in cultured osteosarcoma cells (47).   
The safety of DATS has been shown in cell and animal models, and in humans.  
Treating the normal breast epithelial MCF-10A cell line with 20 or 40 µmol/L DATS 
showed no significant effect on cell viability (39).  Micromolar levels of DATS are 
potentially achievable in vivo as shown by plasma levels of approximately 30 µmol/L 
in rats after receiving a 10 mg injection of DATS administered to the jugular vein 
(27).  In an MCF-7 xenograft model, mice receiving 5 μmol/L DATS by oral gavage 
twice per week displayed a decrease in tumor volume compared to control treated 
animals, and no apparent toxicity was reported (227).  The safety and efficacy of 
DATS for gastric cancer prevention were tested in a clinical intervention study in 
China (31).  Chinese men and women were instructed to take 200 mg of DATS every 
day, in conjunction with 100 µg of selenium every other day.  The intervention was 
found to have a protective effect against development of gastric cancer in Chinese 
men and no harmful side effects were reported, collectively suggesting that DATS is 
safe to consume in large doses, and may play a role in gastric cancer prevention (31). 
In total, studies in cells, animals, and humans suggest an anticancer effect of DATS 





To conclude, our results have shown that DATS suppresses components of the 
Notch signaling pathway which are critically involved in pathway activation in breast 
cancer cells.  Our results also support a non-toxic effect of DATS in untransformed 
breast epithelial cells at similar concentrations, and underscore the long-lasting effect 
of DATS treatment on breast cancer cell proliferation.  Our work lends support to 





CHAPTER 4. CONCLUSIONS 
Breast cancer is a major health concern.  The incidence of breast cancer over the 
past decade has remained stable, underscoring the need for new prevention and 
treatment strategies against this disease (1).  The classical approach of diagnosing and 
treating breast cancer is based on molecular marker expression, e.g. expression of the 
estrogen receptor.  Treating breast cancer based on molecular subtype is effective; 
however, challenges of this approach still arise, including treatment resistance and the 
prevalence of triple-negative breast cancer which lacks targeted treatment strategies 
(7). 
Epidemiological, clinical, translational, and basic research support a role for 
Allium vegetables and their constituents as chemopreventive or anticancer agents 
(17,34,42,43).  DATS has emerged as a highly bioactive component of fresh garlic 
capable of inducing cell cycle arrest and apoptosis in several types of cultured cancer 
cells, including breast cancer cell lines (42,43,227,241).  In the present study, we 
report a novel mechanism of action of DATS on Notch pathway components in breast 
cancer cells.  The rationale behind our investigation is the critical role that Notch 
signaling plays in growth and survival of breast cancer cells.  Notch is a regulator of 
cell proliferation, angiogenesis, EMT, and CSCs (221).  In addition, overexpression 
of Notch was observed in invasive breast cancer compared to normal breast tissue 





Several dietary agents have been investigated for their ability to modulate Notch 
pathway activity in cultured cancer cells and preclinical animal models.  Curcumin 
and genistein are potent Notch inhibitors in several types of cancer cells, and 
downstream effects of treatment with either agent reduces cell and CSC survival, as 
well as activation of pathways downstream of Notch including NF-κB (152,158,172).  
The effect of DATS on Notch signaling pathway has not been identified in breast 
cancer cells. 
We show in our results that DATS inhibits viability, clonogenic survival, alpha 
secretases, and Notch ligands in breast cancer cells.  We assessed the effect of DATS 
on cell viability in estrogen-dependent and estrogen-independent breast cancer cell 
lines and found that DATS induced a dose-dependent decrease in cell growth in 
breast cancer cells independent of estrogen receptor expression.  Importantly, normal-
like breast epithelial cells were more resistant to DATS, suggesting that normal breast 
tissue is affected by DATS treatment to a lesser extent compared to breast cancer 
cells. 
In addition, we observed that DATS had a long-lasting effect on the proliferative 
capacity of breast cancer cells.  The mechanism by which DATS chronically inhibits 
cancer cell proliferation after short exposure periods requires further investigation.  
Published literature has shown that DATS inhibits the breast CSC population (34).  
Additionally, in osteosarcoma cells DATS induces expression of microRNA-34a, -
143, -145, and -200b/c, which play roles in tumor suppression (47).  Modulation of 
CSCs and microRNA networks are two possible mechanisms by which DATS has a 





carcinogenesis in humans (31).  The role of DATS in modulation of epigenetic marks, 
e.g. methylation and acetylation, in cancer cells requires future research, but serves as 
another potential explanation of the lasting effects of DATS treatment in cells and 
humans. 
We report that DATS targets the alpha secretases ADAM10 and ADAM17, and 
the Notch ligands Jagged-1 and Jagged-2 in breast cancer cells.  ADAM10 and 
ADAM17 are each inversely associated with survival in breast cancer, and play a 
critical role in Notch pathway activation (65,66,226).  Jagged-1 and Jagged-2 play 
instrumental roles in Notch pathway initiation, and are frequently overexpressed in 
invasive breast cancer compared to normal breast tissue (58).  We therefore conclude 
that our data show inhibition of significant and relevant proteins in breast cancer cells, 
and support further investigation of DATS in preclinical models of breast cancer 
progression.   
The mechanism by which DATS inhibits expression of ADAM10 and 
ADAM17 in breast cancer cells requires future research.  Our results do not show a 
strong inhibitory effect of DATS on ADAM10 mRNA, suggesting that inhibition of 
ADAM10 protein occurs at the translational level, post-translational level, or some 
combination of the two.  Furthermore, our results suggest that DATS more robustly 
inhibits expression of active ADAM10 compared to the ADAM10 precursor, 
indicating that DATS may play a role in inhibiting expression or activity of 
proprotein convertase-7 or furin.  Future research determining the effect of DATS on 





of ADAM10 and ADAM17 will provide valuable information of DATS’s mechanism 
of action against alpha secretases in cancer cells.   
Successful use of DATS in a clinical setting will require a broader 
understanding of its anticancer effects in cell and animal models and its 
pharmacokinetics in humans.  Animal models identifying the effect of DATS on 
ADAM10 expression in tumor tissue are essential.  In addition, the safety of DATS 
combined with anticancer drugs must be tested in animal models, as toxic drug-drug 
interactions may limit overall treatment efficacy.  Understanding DATS 
pharmacokinetics is required for evaluation of DATS as an anticancer agent in 
humans.  Identifying the process of gut absorption and subsequent metabolism or 
storage of DATS in body organs will broaden our understanding of potential 
requirements for modified DATS analogs or drug delivery systems which extend the 
half-life and clinical efficacy of the drug in humans.  While some clinical data are 
available (31), pharmacokinetic evaluation of DATS will also reveal levels of DATS 
which are safe for human consumption.  The results of the present study contribute to 
a growing body of basic evidence to support further investigation of DATS as an 
anticancer agent in breast cancer.  
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